

Oncopeptides Operational Update Q2 2019

August 28, 2019

Jakob Lindberg, CEO



Disclaimer

IMPORTANT: You must read the following before continuing. The following applies to this document, the oral presentation of the information in this document by Oncopeptides AB (the “Company”) or any person on behalf of the Company, and any question-and-answer session that follows the oral presentation (collectively, the “Information”). In accessing the Information, you agree to be bound by the following terms and conditions.

The Information is confidential and may not be reproduced, redistributed, published or passed on to any other person, directly or indirectly, in whole or in part, for any purpose. This document may not be removed from the premises. If this document has been received in error it must be returned immediately to the Company.

The Information is not intended for potential investors and does not constitute or form part of, and should not be construed as an offer or the solicitation of an offer to subscribe for or purchase securities of the Company, and nothing contained therein shall form the basis of or be relied on in connection with any contract or commitment whatsoever. This document and its contents may not be viewed by persons within the United States or “U.S. Persons” (as defined in Regulation S under the Securities Act of 1933, as amended (the “Securities Act”) unless they are qualified institutional buyers “QIBs” as defined in Rule 144A under the Securities Act. By accessing the Information, you represent that you are (i): a non-U.S. person that is outside the United States or (ii) a QIB. This document and its contents may not be viewed by persons within the United Kingdom unless they are persons with professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 as amended (the “Order”), or high net worth entities falling within Article 49(2)(a) to (d) of the Order (each a “Relevant Person”). By accessing the Information, you represent that you are: (i) outside the United Kingdom or (ii) a Relevant Person.

The Information has been prepared by the Company, and no other party accepts any responsibility whatsoever, or makes any representation or warranty, express or implied, for the contents of the Information, including its accuracy, completeness or verification or for any other statement made or purported to be made in connection with the Company and nothing in this document or at this presentation shall be relied upon as a promise or representation in this respect, whether as to the past or the future.

The Information contains forward-looking statements. All statements other than statements of historical fact included in the Information are forward-looking statements. Forward-looking statements give the Company’s current expectations and projections relating to its financial condition, results of operations, plans, objectives, future performance and business. These statements may include, without limitation, any statements preceded by, followed by or including words such as “target,” “believe,” “expect,” “aim,” “intend,” “may,” “anticipate,” “estimate,” “plan,” “project,” “will,” “can have,” “likely,” “should,” “would,” “could” and other words and terms of similar meaning or the negative thereof. Such forward-looking statements involve known and unknown risks, uncertainties and other important factors beyond the Company’s control that could cause the Company’s actual results, performance or achievements to be materially different from the expected results, performance or achievements expressed or implied by such forward-looking statements. Such forward-looking statements are based on numerous assumptions regarding the Company’s present and future business strategies and the environment in which it will operate in the future.


No representation, warranty or undertaking, express or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the Information or the opinions contained therein. The Information has not been independently verified and will not be updated. The Information, including but not limited to forward-looking statements, applies only as of the date of this document and is not intended to give any assurances as to future results. The Company expressly disclaims any obligation or undertaking to disseminate any updates or revisions to the Information, including any financial data or forward-looking statements, and will not publicly release any revisions it may make to the Information that may result from any change in the Company’s expectations, any change in events, conditions or circumstances on which these forward-looking statements are based, or other events or circumstances arising after the date of this document. Market data used in the Information not attributed to a specific source are estimates of the Company and have not been independently verified.

Overview of our present clinical development program in multiple myeloma




The second quarter was our most eventful quarter since the IPO

- **Positive feed-back from the FDA regarding HORIZON**
 - Submission preparations ongoing for accelerated approval application with target submission date Q1 2020
- **Strengthened patent protection in the US**
 - US Patent Office granted additional patents for melflufen in the United States
- **New data presented at EHA**
 - HORIZON continued to show clinical benefit in multi-refractory RRMM patients
 - ANCHOR showed significant promise in combining melflufen with both proteasome inhibitors and anti-CD38 therapies in RRMM patients



Good news continued over the summer

- **Financial positioned strengthened**
 - 683 MSEK in additional capital raised to enable pre-commercialisation activities and build-up, as well as broadening of our clinical development program
- **Late-breaker oral presentation accepted at the International Myeloma Workshop (IMW) meeting in Boston in September**
 - IMW will now be an important clinical data update conference for us
 - Focus will be on RRMM patients with extramedullary disease (EMD)



Financial results for the period Jan – Jun 2019




- Operating loss increased to SEK 305.6 M (loss:205.1)
 - R&D increase primarily due to increase in Clinical & drug supply: SEK 201.4 M (135.5)
 - OCEAN costs SEK 110.7 M (69.4)
 - HORIZON costs SEK 29.5 (12.6)
 - ANCHOR costs SEK 19.4 M (12.0)
 - Build-up of commercial and medical relations explains increase in M&S costs
- Operating costs include non-cash costs related to incentive programs
 - SEK 17.8 M (50.2) for H1
- Cash flow from operating activities neg. SEK 265.8 M (neg. 130.6)
- Cash position was SEK 626.8 M (568.2) as of June 30, 2019
 - Directed share issue raised SEK 514.8 M after issue costs in January 2019
 - Second share issue raising SEK 682.9 M was completed in July

The next 12 months represents the most information rich period in Oncopeptides' history

H2 2019	H1 2020
FPI Amyloidosis Trial	NDA submission
FPI LIGHTHOUSE	LPI OCEAN
LPI HORIZON	LPI ANCHOR
LPI BRIDGE	Top-line results OCEAN
Updated Data from HORIZON on EMD patients at IMW	
Updated Data from HORIZON, ANCHOR and BRIDGE at ASH	

Q&A



***Thank you for
your attention!***

